LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will p
Continued advancement of platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Further strengthened leading intellectual property (IP) position with issuance of new patent in the United S
… this program from Ionis Pharmaceuticals in October 2018. Scientific Updates During the second quarter of 2019, the … Company presented new data on the ProQR portfolio at three scientific conferences, including the annual meeting of … the Company presented at the 2019 annual Usher connections conference in July 2019. Business Updates In May 2019, …
